Enliven Therapeutics (ELVN) shares are soaring 5.93% in pre-market trading on Thursday, buoyed by recent bullish analyst ratings. The surge comes on the heels of two prominent Wall Street firms reaffirming their positive outlook on the biotech company.
BTIG analyst Justin Zelin reiterated a Buy rating on Enliven Therapeutics early Thursday, setting an ambitious price target of $45.00. This target suggests significant upside potential from the stock's previous closing price of $19.99. Additionally, TD Cowen analyst Phil Nadeau maintained his Buy rating on the company in a report released late Wednesday.
The back-to-back bullish ratings from respected analysts appear to have boosted investor confidence in Enliven Therapeutics' prospects. As the biotech sector continues to attract attention, ELVN's strong pre-market performance indicates that market participants are responding positively to the analysts' optimistic views on the company's future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。